Request To Download Free Sample of This Strategic Report @ Highlighted with 111 tables and 87 figures, this 211-page report ?Global Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...

GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 ...

GSK is prioritizing development of its hepatitis ... placebo—but the idea was to prime the immune system with a viral vector encoding hepatitis B protein antigens, boost the immune system ...

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments. The British pharmaceutical giant said Wednesday that the 2.0 billion ...

Pharmaceuticals giant GlaxoSmithKline (GSK.L) (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline. It came as the boss of the London-listed firm cheered an “excellent” ...

GSK said it now e American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast.

(Reuters) -GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and cancer drugs ...

Thermo Fisher’s office in Cambridge, Massachusetts. Image credit: Shutterstock/Tada Images. Thermo Fisher is cutting the headcount at two of its US facilities by 300 as the company continues to ...